20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
20:23 , Dec 22, 2017 |  BC Week In Review  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
22:29 , Dec 18, 2017 |  BC Extra  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
07:00 , Aug 13, 2015 |  BC Innovations  |  Tools & Techniques

Helping Beethoven hear

Little progress has been made in developing therapies for hearing loss that go beyond the temporary and partial solutions provided by hearing aids and cochlear implants, and most company activity is focused on acquired forms...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

AUT00063: Phase IIa started

Autifony began the double-blind, placebo-controlled, U.K. Phase IIa QUIET-1 trial to evaluate 800 mg oral AUT00063 once daily for 28 days in about 152 patients. Autifony Therapeutics Ltd. , London, U.K.   Product: AUT00063  ...
07:00 , Jun 17, 2013 |  BioCentury  |  Emerging Company Profile

Autifony: Sense and sensitivity

Autifony Therapeutics Ltd. is developing compounds for hearing loss and tinnitus that modulate potassium channel Kv3 , a target on inhibitory receptors of the CNS that may affect central auditory processing of speech and other...